


La compañía biotecnológica Biocross presentará un innovador test para la determinación en 10 minutos del riesgo de desarrollar la enfermedad de Alzheimer
El Alzheimer, enfermedad neurodegenerativa, afecta actualmente a 37 millones de personas en todo el mundo y se espera que la cifra aumente a 131 millones en 2050 El test de riesgo ApoE4 Blood Marker Assay es una prueba en sangre, coste-efectiva y contrastada que...
ApoE4 blood marker assay. A new non-genetic method to evaluate Alzheimer´s disease risk using clinical chemistry platforms
Biocross was pleased to present at the 9th Clinical trials on Alzheimer’s Disease (CTAD) meeting, to be held in San Diego, the ApoE4 blood marker assay, a new non-genetic method to evaluate Alzheimer’s disease risk. To date only the presence of one or two APOE ε4...
Biocross presents at Bio-Europe 2016
Biocross S.L., a biotechnology company focused on the development of innovative technologies for the diagnosis of Alzheimer’s disease and the identification of at-risk individuals, today announced that their Chief Executive Officer Matt Mittino will present the...
Biospain 2016 – Company Presentation
Biocross to participate in the 8th International Meeting on Biotechnology, Biospain 2016, which takes place in Bilbao (Vizcaya), September 28–30, 2016. Biospain has become the main scientific, social, commercial, and industrial meeting point of the biotechnological...